Cellect Biotechnology Ltd. (APOP)’s Stock Is Sell After Forming Double Bottom Pattern

June 23, 2018 - By Linda Rogers

The chart of Cellect Biotechnology Ltd. (APOP) shows a double bottom with $6.48 target or 9.00 % below today’s $7.12 share price. The 6 months chart pattern indicates high risk for the $45.20 million company. It was reported on Jun, 23 by Finviz.com. If the $6.48 price target is reached, the company will be worth $4.07M less. Double bottoms are rare but powerful chart patterns.

The stock decreased 0.42% or $0.03 during the last trading session, reaching $7.12. About 5,660 shares traded. Cellect Biotechnology Ltd. (NASDAQ:APOP) has declined 26.23% since June 23, 2017 and is downtrending. It has underperformed by 38.80% the S&P500.

Analysts await Cellect Biotechnology Ltd. (NASDAQ:APOP) to report earnings on August, 20. They expect $-0.29 earnings per share, down 26.09 % or $0.06 from last year’s $-0.23 per share. After $-0.16 actual earnings per share reported by Cellect Biotechnology Ltd. for the previous quarter, Wall Street now forecasts 81.25 % negative EPS growth.

Another recent and important Cellect Biotechnology Ltd. (NASDAQ:APOP) news was published by Seekingalpha.com which published an article titled: “Magenta Therapeutics on deck for IPO” on May 25, 2018.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. The company has market cap of $45.20 million. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: